W Lorelli
Overview
Explore the profile of W Lorelli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
95
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cue D, Southern S, Southern P, Prabhakar J, Lorelli W, Smallheer J, et al.
Proc Natl Acad Sci U S A
. 2000 Mar;
97(6):2858-63.
PMID: 10706638
Streptococcus pyogenes can be efficiently internalized by a variety of human epithelial cells. beta-lactam antibiotics, commonly used to treat S. pyogenes infections, do not readily permeate mammalian cells. There is...
2.
Mousa S, Lorelli W, Campochiaro P
J Cell Biochem
. 1999 Jun;
74(1):135-43.
PMID: 10381270
The retinal pigmented epithelium (RPE) is a monolayer of polarized cells located between retinal photoreceptors and blood vessels of the choroid. The basal surface of RPE cells rests on Bruch's...
3.
Mousa S, Lorelli W, Mohamed S, Batt D, Jadhav P, Reilly T
J Cardiovasc Pharmacol
. 1999 Apr;
33(4):641-6.
PMID: 10218736
This study was undertaken to define the alphavbeta3 binding affinity and specificity of the low-molecular-weight nonpeptide integrin antagonist, SM256. SM256 demonstrated high potency (IC50, 0.057+/-0.030 nM) in inhibiting vitronectin binding...
4.
Mousa S, Bozarth J, Lorelli W, Forsythe M, Thoolen M, Slee A, et al.
J Pharmacol Exp Ther
. 1998 Sep;
286(3):1277-84.
PMID: 9732389
Recent advances in the development of i.v. platelet glycoprotein alphaIIb/beta3 integrin (GPIIb/IIIa) antagonists led to the development of either a class of small-molecular-weight antagonists with a short to ultra-short duration...
5.
Mousa S, Olson R, Bozarth J, Lorelli W, Forsythe M, Racanelli A, et al.
J Cardiovasc Pharmacol
. 1998 Aug;
32(2):169-76.
PMID: 9700976
This study was undertaken to define the platelet glycoprotein alphaIIb beta3 integrin (GPII/IIIa) affinity, specificity, and oral antiplatelet efficacy of DMP 802, a small-molecule nonpeptide antiplatelet agent. Platelet GPIIb/IIIa integrin...
6.
Mousa S, Forsythe M, Lorelli W, Bozarth J, Xue C, Wityak J, et al.
Coron Artery Dis
. 1996 Oct;
7(10):767-74.
PMID: 8970768
Objective: To define the antiplatelet efficacy and specificity of the glycoprotein IIb/IIIa complex (GPIIb/IIIa) antagonist prodrug DMP754 and its free acid form, XV459. Methods And Materials: DMP754 has an IC50...
7.
Mousa S, Flint S, Lorelli W, Hassell S, Bozarth J, De Grado W, et al.
Thromb Res
. 1994 Oct;
76(2):109-19.
PMID: 7863463
DMP 728, cyclo (D-2-aminobutyrate-N-Methyl-L-Arginyl-Glycyl-L-Aspartyl- 3-amino-methyl-benzoic acid) methanesulfonate salt, is a novel antiplatelet agent with high affinity and specificity for human and canine platelet GPIIb/IIIa (alpha 2/beta 3) receptors. DMP 728...
8.
Mousa S, Bozarth J, Forsythe M, Lorelli W, Thoolen M, Ramachandran N, et al.
Cardiology
. 1993 Jan;
83(5-6):374-82.
PMID: 7509257
The present study was undertaken to define the platelet GPIIb/IIIa affinity and specificity of DMP728, the cyclic [(D-2-aminobutyrate-N-methyl-L-arginyl-glycyl-L-aspartyl)-3-aminomethyl- benzoic acid] methane sulfonate. DMP728 demonstrated similar potency (IC50 = 0.046 +/-...